The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Clearing Glaucoma's Cellular Clutter
Glaucoma Neuro-ophthalmology News

Clearing Glaucoma's Cellular Clutter

Pharmacologically restoring mitochondrial clearance for impaired autophagy could offer new neuroprotection route

11/17/2026 2 min read

Share

  • Full Article
  • Summary
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Clinical Report: Clearing Glaucoma's Cellular Clutter

Overview

Preclinical research by Maddineni and colleagues links impaired autophagy and mitophagy to abnormal mitochondrial accumulation, oxidative damage, and retinal ganglion cell (RGC) degeneration in glaucoma models. Torin 2 increased mitophagy and preserved RGC measures in a mouse model without changing intraocular pressure (IOP), and increased RGC survival in an ex vivo human retinal explant model; the findings are not clinical evidence of efficacy.

Background

IOP reduction remains the established approach to preserving visual function in glaucoma, but RGC loss may continue despite pressure control. The European Glaucoma Society states that reducing IOP is the only proven method of preserving visual function. The study examined whether failure to clear damaged mitochondria could contribute to ongoing neurodegeneration. Its experiments used mouse glaucoma models, mitophagy reporter mice, RGC-specific genetic manipulation, and ex vivo human retinal tissue.

Data Highlights

Experiment or measureReported result
Mitophagy after five weeks of ocular hypertensionSignificantly reduced mitochondrial clearance, detected before measurable RGC loss and axonal degeneration
RGC-specific Atg5 disruption, assessed six weeks laterApproximately 39% RGC loss and around 59% loss of healthy optic nerve axons
Torin 2 in glucocorticoid-induced mouse glaucomaMean pattern electroretinography amplitude: 31.82 µV in treated hypertensive eyes versus 17.36 µV in control-treated hypertensive eyes
Torin 2-associated structural measures in the mouse model37% increase in RGC number and 51% increase in morphologically intact axons
Torin 2 in ex vivo human retinal explantsApproximately 49.7% increase in RGC survival under neurotrophic factor-deprived conditions

Key Findings

  • Sustained IOP elevation was associated with swollen mitochondria with disorganized or fragmented cristae in RGCs and optic nerve axons, alongside increased markers of mitochondrial accumulation and oxidative DNA damage.
  • Mitophagy reporter experiments detected reduced mitochondrial clearance after five weeks of ocular hypertension, before detectable RGC loss and axonal degeneration; impairment persisted after neurodegeneration was established.
  • RGC-specific disruption of Atg5 was followed by abnormal mitochondrial accumulation, oxidative DNA damage, impaired RGC function, approximately 39% RGC loss, and around 59% loss of healthy optic nerve axons.
  • In the glucocorticoid-induced mouse model, intravitreal Torin 2 increased mitophagy and preserved RGC function without altering IOP; treated hypertensive eyes had higher mean pattern electroretinography amplitudes than control-treated hypertensive eyes.
  • Torin 2 was associated with a 37% increase in RGC number and a 51% increase in morphologically intact axons in the mouse model, and approximately 49.7% greater RGC survival in ex vivo human retinal explants.
  • The authors noted that some neuroprotection in the myocilin model may have resulted from an accompanying IOP reduction and that broad mTOR inhibition may complicate translation; they proposed further study of more selective autophagy or mitophagy modulators.

Clinical Implications

The findings are preclinical and do not establish Torin 2 as a treatment for patients with glaucoma. The authors identify selective autophagy or mitophagy modulators and pathway-specific interventions as subjects for future research; current clinical guidance continues to identify IOP reduction as the proven means of preserving visual function.

Conclusion

The study associates impaired mitochondrial clearance with RGC degeneration and reports protective effects of autophagy activation in experimental models. Whether selective targeting of these pathways can provide clinical neuroprotection remains to be established.

Related Resources & Content

  1. Maddineni P, et al., Molecular Neurodegeneration, year not provided -- Study of autophagy, mitophagy, and glaucoma described in the supplied article
  2. European Glaucoma Society, 2025 -- Terminology and Guidelines for Glaucoma, 6th Edition
  3. Heijl A, et al., Archives of Ophthalmology, 2002 -- Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
  4. Glaucoma Physician, 2020 -- Identifying Cell Degeneration in Glaucoma
  5. Glaucoma Physician — Treatment of Severe Ocular Surface Disease in the Glaucoma Patient Recommendations
  6. Ophthalmology Management — Mitigating Ocular Surface Disease in Patients With Glaucoma
  7. Ophthalmology Management — Mitigating Ocular Surface Disease in Patients With Glaucoma
  8. European Glaucoma Society – Terminology and Guidelines for Glaucoma, 6th Edition
  9. Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
  10. Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
  11. Evaluating Primary Treatment for People with Advanced Glaucoma: Five-Year Results of the Treatment of Advanced Glaucoma Study

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: